On the evening of January21, 2020, Moderna, Inc. provided a statement to a news outlet regarding its participation in the potential creation of a vaccine to respond to the current public health threat of the coronavirus labeled 2019-nCoV.
The statement read:
“Moderna’s mRNA vaccine technology could serve as a rapid and flexible platform that may be useful in responding to newly emerging viral threats, such as the novel coronavirus. While we have not previously tested this rapid response capability, Moderna confirms that we are working with NIH/NIAID/VRC on a potential vaccine response to the current public health emergency. Moderna is committed to addressing infectious diseases and improving global public health.”
